Zhenagen
/ Khavinson-tradition testicular / reproductive bioregulatorALIAS · Zhenagen · Testis peptide bioregulator · Reproductive peptide bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Zhenagen is a Khavinson-tradition peptide bioregulator presented as a testicular / reproductive-tissue extract or peptide derivative. As with the broader cytogen and tripeptide series from the Saint Petersburg programme, the molecule has Russian-language descriptive material but essentially no PubMed-indexed Western primary characterisation.
Within the Khavinson framework, zhenagen is positioned as a tissue-selective peptide bioregulator of the testicular and reproductive axis, proposed to modulate spermatogenesis-related transcription and Leydig / Sertoli cell function. The molecular pharmacology invoked is the same direct-DNA-binding transcription-modulation hypothesis that the broader programme has applied to other organ-targeted bioregulators; the specific molecular interactions have not been characterised in indexed Western primary literature.
Tier 4. Discussion is confined to Russian-language sources from the Khavinson group and immediate collaborators. No Phase 1 or later trial in Western literature; no peer-reviewed structural or pharmacological characterisation of sufficient detail for independent identity confirmation.
No formal Phase 1 human safety database in Western literature.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature without independent Western replication. The reproductive / testicular positioning of zhenagen rests on the Khavinson programme's tissue-selective bioregulator hypothesis, which has not been independently corroborated. Vendor product identity and pharmacology are not externally verifiable.